118 related articles for article (PubMed ID: 35191169)
1. Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists.
Kushnir I; Clemons M; Fergusson D; Bossé D; Reaume MN
J Eval Clin Pract; 2022 Jun; 28(3):495-499. PubMed ID: 35191169
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
4. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
[TBL] [Abstract][Full Text] [Related]
5. Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report.
Gill S; Hao D; Hirte H; Campbell A; Colwell B
Curr Oncol; 2020 Apr; 27(2):71-74. PubMed ID: 32489248
[TBL] [Abstract][Full Text] [Related]
6. Barriers to participation in clinical trials: a physician survey.
Mahmud A; Zalay O; Springer A; Arts K; Eisenhauer E
Curr Oncol; 2018 Apr; 25(2):119-125. PubMed ID: 29719427
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
Dudani S; Leighl NB; Ho C; Pantarotto JR; Zhu X; Zhang T; Wheatley-Price P
Lung Cancer; 2016 Apr; 94():74-80. PubMed ID: 26973210
[TBL] [Abstract][Full Text] [Related]
9. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
10. Referral practices of oncologists to specialized palliative care.
Wentlandt K; Krzyzanowska MK; Swami N; Rodin GM; Le LW; Zimmermann C
J Clin Oncol; 2012 Dec; 30(35):4380-6. PubMed ID: 23109708
[TBL] [Abstract][Full Text] [Related]
11. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study.
Benson AB; Pregler JP; Bean JA; Rademaker AW; Eshler B; Anderson K
J Clin Oncol; 1991 Nov; 9(11):2067-75. PubMed ID: 1941065
[TBL] [Abstract][Full Text] [Related]
12. Oncologists' opinions towards recommending exercise to patients with cancer: a Canadian national survey.
Jones LW; Courneya KS; Peddle C; Mackey JR
Support Care Cancer; 2005 Nov; 13(11):929-37. PubMed ID: 15809835
[TBL] [Abstract][Full Text] [Related]
13. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.
Peppercorn J; Burstein H; Miller FG; Winer E; Joffe S
J Clin Oncol; 2008 Dec; 26(36):5994-6000. PubMed ID: 19029413
[TBL] [Abstract][Full Text] [Related]
14. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
16. How informative are open-label studies for youth with bipolar disorder? A meta-analysis comparing open-label versus randomized, placebo-controlled clinical trials.
Biederman J; Petty CR; Woodworth KY; Lomedico A; O'Connor KB; Wozniak J; Faraone SV
J Clin Psychiatry; 2012 Mar; 73(3):358-65. PubMed ID: 22154898
[TBL] [Abstract][Full Text] [Related]
17. Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
Sutherland S; Meiser B; Kaur R; Mitchell G; Kirk J; Peate M; Tim Wong WK; Goodwin A
Breast J; 2019 Jan; 25(1):34-40. PubMed ID: 30525267
[TBL] [Abstract][Full Text] [Related]
18. The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
van de Laar R; Zusterzeel PL; Van Gorp T; Ottevanger PB; Massuger LF; Kruitwagen RF
Gynecol Oncol; 2013 Dec; 131(3):561-6. PubMed ID: 24060415
[TBL] [Abstract][Full Text] [Related]
19. Are Future Radiation Oncologists Equipped With the Knowledge to Manage Elderly Patients With Cancer?
Morris L; Thiruthaneeswaran N; Lehman M; Hasselburg G; Turner S
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):743-747. PubMed ID: 28258899
[TBL] [Abstract][Full Text] [Related]
20. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
